NeuroStar® Marks Two Years of Transformative Impact with NeuroStar University
Neuronetics, Inc. (NASDAQ: STIM) celebrates the two-year anniversary of NeuroStar University (NSU), its innovative training facility for healthcare providers using NeuroStar TMS Therapy. The milestone event in Charlotte, North Carolina, will feature award-winning patient advocate Martha Rhodes, author of '3,000 Pulses Later'. NSU has trained over 678 NeuroStar providers, with attendees treating an average of 61% more patients compared to non-attendees.
The celebration includes a private book signing with Martha Rhodes and a fireside chat between Rhodes and Neuronetics CEO Keith Sullivan. NSU's impact on clinical training and patient care will be highlighted, showcasing its role in elevating standards for treating treatment-resistant depression.
Neuronetics, Inc. (NASDAQ: STIM) festeggia il secondo anniversario di NeuroStar University (NSU), la sua innovativa struttura di formazione per i professionisti sanitari che utilizzano la Terapia TMS di NeuroStar. L'evento di celebrazione si terrà a Charlotte, North Carolina, e vedrà la partecipazione dell'attrice premio paziente Martha Rhodes, autrice di '3.000 Pulsazioni Dopo'. NSU ha formato oltre 678 fornitori di NeuroStar, con i partecipanti che trattano in media il 61% di pazienti in più rispetto ai non partecipanti.
La celebrazione include una firma di libri privata con Martha Rhodes e una chiacchierata davanti al camino tra Rhodes e Keith Sullivan, CEO di Neuronetics. L'impatto di NSU sulla formazione clinica e sulla cura dei pazienti sarà messo in luce, evidenziando il suo ruolo nell'elevare gli standard per il trattamento della depressione resistente al trattamento.
Neuronetics, Inc. (NASDAQ: STIM) celebra el segundo aniversario de NeuroStar University (NSU), su innovadora instalación de formación para proveedores de atención médica que utilizan la Terapia TMS de NeuroStar. El evento conmemorativo en Charlotte, Carolina del Norte, contará con la presencia de la defensora de pacientes galardonada Martha Rhodes, autora de '3,000 Pulsos Después'. NSU ha capacitado a más de 678 proveedores de NeuroStar, con los asistentes tratando un 61% más de pacientes en promedio en comparación con los no asistentes.
La celebración incluye una firma de libros privada con Martha Rhodes y una charla junto al fuego entre Rhodes y Keith Sullivan, CEO de Neuronetics. Se destacará el impacto de NSU en la formación clínica y el cuidado de pacientes, mostrando su papel en la elevación de los estándares para tratar la depresión resistente al tratamiento.
Neuronetics, Inc. (NASDAQ: STIM)는 NeuroStar University (NSU)의 2주년 기념일을 축하합니다. NeuroStar TMS 치료를 사용하는 의료 제공자를 위한 혁신적인 교육 시설입니다. 노스캐롤라이나주 샬럿에서 열리는 이번 기념행사는 '3,000 Pulses Later'의 저자이자 수상 경력이 있는 환자 옹호자 Martha Rhodes가 참가합니다. NSU는 678명 이상의 NeuroStar 제공자를 교육했으며, 참석한 제공자는 비참석자에 비해 평균 61% 더 많은 환자를 치료하고 있습니다.
이번 기념 행사에는 Martha Rhodes와의 비공식 서명 이벤트와 Rhodes와 Neuronetics CEO Keith Sullivan 간의 대화가 포함됩니다. NSU의 임상 교육 및 환자 치료에 대한 영향력이 강조되며, 치료 저항성 우울증 치료를 위한 기준을 높이는 데 기여하는 역할이 부각될 것입니다.
Neuronetics, Inc. (NASDAQ: STIM) célèbre le deuxième anniversaire de NeuroStar University (NSU), son installation de formation innovante pour les professionnels de santé utilisant la thérapie TMS NeuroStar. L'événement marquant qui se déroulera à Charlotte, Caroline du Nord, mettra en vedette l'avocate des patients primée Martha Rhodes, auteure de '3.000 Pulses Later'. NSU a formé plus de 678 fournisseurs de NeuroStar, avec une moyenne de 61 % de patients supplémentaires traités par les participants par rapport aux non-participants.
La célébration comprend une séance de dédicace privée avec Martha Rhodes et une discussion au coin du feu entre Rhodes et Keith Sullivan, PDG de Neuronetics. L'impact de NSU sur la formation clinique et les soins aux patients sera mis en avant, montrant son rôle dans l'amélioration des normes de traitement de la dépression résistante au traitement.
Neuronetics, Inc. (NASDAQ: STIM) feiert das zwei-jährige Bestehen der NeuroStar University (NSU), seiner innovativen Ausbildungseinrichtung für Gesundheitsdienstleister, die die NeuroStar-TMS-Therapie nutzen. Die feierliche Veranstaltung in Charlotte, North Carolina, wird die preisgekrönte Patientenanwältin Martha Rhodes, Autorin von '3.000 Pulses Later', präsentieren. NSU hat über 678 NeuroStar-Anbieter ausgebildet, wobei die Teilnehmer im Durchschnitt 61 % mehr Patienten behandeln als Nicht-Teilnehmer.
Die Feier umfasst eine private Buchsignierung mit Martha Rhodes und ein Feuerstuhlgremium zwischen Rhodes und Keith Sullivan, CEO von Neuronetics. Der Einfluss von NSU auf die klinische Ausbildung und die Patientenversorgung wird hervorgehoben, wobei die Rolle gezeigt wird, die sie bei der Erhöhung der Standards für die Behandlung von therapieresistenter Depression spielt.
- NSU-trained providers treat 61% more patients on average compared to non-attendees
- Over 678 NeuroStar providers trained at NSU in two years
- NSU is the only program of its kind in the neurobehavioral space
- None.
Celebrating milestones in patient care and practice enhancement through NeuroStar’s innovative training facility
MALVERN, Pa., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, proudly announces the two-year anniversary of NeuroStar University (NSU). This milestone will be celebrated with a special event held at the NSU training center in Charlotte, North Carolina, showcasing the profound impact of NSU's pioneering training programs on pioneering new standards in patient care and responsiveness.
"NeuroStar University is a key part of our ongoing commitment to supporting our healthcare providers. The skills they gain through this training directly enhance the care they deliver with NeuroStar's innovative therapy, making a real impact in the lives of people with treatment-resistant depression," said Keith J. Sullivan, President and CEO of Neuronetics, Inc. "We're especially grateful for Martha's presence here today and her exceptional dedication and support to help tell the stories of people who have overcome depression. We look forward to building on the success of NSU for many years to come.”
The celebration will commence Tuesday, August 20, with a private book signing and meet-and-greet event featuring award-winning patient advocate Martha Rhodes, author of the book 3,000 Pulses Later. The following day, NSU will host a day of classes that begins with a featured fireside chat and Q&A between Martha Rhodes and NeuroStar CEO Keith Sullivan. This discussion will showcase the vital role NSU plays in elevating clinical training and enhancing the patient experience.
“I’m thrilled to be part of NeuroStar’s journey and to see the difference they’re making in mental health care,” said Martha Rhodes. “NeuroStar University’s commitment to cutting-edge education and patient support is remarkable, and I’m eager to share my experiences and contribute to this important dialogue.”
Over the past two years, NSU has become a beacon of excellence for healthcare professionals seeking advanced TMS education, having trained over 678 NeuroStar providers. As the only program of its kind in the neurobehavioral space, NSU offers practices an unparalleled opportunity to analyze, enhance, and elevate their NeuroStar business through advanced clinical trainings and practice development. As a result, these attendees treat an average of
For more information about NeuroStar TMS Therapy, please visit www.neurostar.com.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15-21 with MDD. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with over 6.6 million treatments delivered. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, visit www.neurostar.com.
Media Contact:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com
FAQ
What is NeuroStar University (NSU) and how does it impact patient care for Neuronetics (STIM)?
How many providers has NeuroStar University trained since its inception?
Who is Martha Rhodes and what is her role in the NeuroStar University anniversary event?
What makes NeuroStar University unique in the neurobehavioral space?
